Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteoporosis
Evista patent challenge confirmed
December 26th, 2002
Barr Laboratories, Inc., (BRL) confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food & Drug Administration (FDA) for Eli Lily's Evista 60 mg Tablet (raloxifene hydrochloride). Barr's ANDA alleges that the Orange Book listed patents for Evista are invalid or would not be infringed by Barr's ANDA Product. Eli Lilly disclosed in its SEC form 10-Q that Barr had filed an ANDA challenging the patents and that Lilly intends to defend the patents. Evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Evista has current annual sales of approximately $635 million. ...
Source: Women's Health Weekly (2002-12-26)
|
